Sign In
Last checked at 
3 Feb 2020 09:00
03 February 2020
IXICO plc
("IXICO" or the "Company")
IXICO Supports the Alzheimer's Disease Neuroimaging Initiative
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announced funding support for the Alzheimer's Disease Neuroimaging Initiative (ADNI), and two of their scientists will join the ADNI-Private Partner Scientific Board (PPSB).
ADNI is a longitudinal multicentre study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). Its goals are to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease's progression with biomarkers, as well as to support advances in AD intervention, prevention, and treatment through the application of new diagnostic methods in a pre-competitive environment and through data sharing to advance the field in AD.
Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are proud to support the ADNI initiative which has made a major contribution to setting the imaging standards in AD research and provides access to important clinical data sets to the global research community. ADNI's purpose is well-aligned with our own goal to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare which will contribute to the advancement of AD research. We look forward to engaging with all members of the consortium to contribute to the success of this initiative."
The ADNI-PPSB, convened by the Foundation for the National Institutes of Health, facilitates open dialogue around the progress of the ADNI project, as well as new trends with Alzheimer's disease-related research and development. "The FNIH is pleased to welcome IXICO to the ADNI-PPSB," said Joseph Menetski, Ph.D., Associate Vice President, FNIH. "IXICO's expertise in data analytics will be a valuable contribution to the role the ADNI-PPSB plays to help develop biomarkers that advance the field of Alzheimer's disease research."
For further information please contact:
IXICO plc | +44 (0) 20 3763 7498 |
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer | |
Optimum Strategic Communications | +44 (0) 203 950 9144 |
Mary Clark / Supriya Mathur / Manel Mateus | |
IXICO@optimumcomms.com |
About IXICO
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
Follow the stocks
